{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:34:43Z","timestamp":1793093683288,"version":"4.5.0"},"reference-count":52,"publisher":"American Chemical Society (ACS)","issue":"5","license":[{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T00:00:00Z","timestamp":1576627200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-045"}],"funder":[{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2018ZX09301002-002"],"award-info":[{"award-number":["2018ZX09301002-002"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002949","name":"Government of Jiangsu Province","doi-asserted-by":"publisher","award":["BC2015122"],"award-info":[{"award-number":["BC2015122"]}],"id":[{"id":"10.13039\/501100002949","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>TNP-2092 is a unique multitargeting drug conjugate with extremely low propensity for development of resistance. The in vitro activity of TNP-2092 against a panel of urease-producing bacteria was similar to that of rifaximin, a locally acting antibiotic approved for the treatment of hepatic encephalopathy, irritable bowel syndrome with diarrhea, and traveler\u2019s diarrhea. When given orally, TNP-2092 exhibited low absorption and the majority of compound was recovered in feces as parent. The impact of oral TNP-2092 on gut microbiota was investigated in rats. TNP-2092 was administered to rats by oral gavage for 7 days. Feces samples were collected and analyzed by 16S rRNA sequencing. Although the total amount of bacterial load appeared relatively unchanged before, during, and after treatment, significant changes in the relative abundance of certain gut bacteria at family and genus levels were observed. Some of the changes are known to be associated with improvement of symptoms associated with liver cirrhosis and hepatic encephalopathy. The observed effects of TNP-2092 on gut microbiota in rats were similar to those of rifaximin. In vivo, TNP-2092 demonstrated potent efficacy in a mouse Clostridium difficile infection model, superior to metronidazole and vancomycin, with no relapse observed after treatment. TNP-2092 is currently in clinical development for the treatment of symptoms associated with gastrointestinal and liver disorders.<\/jats:p>","DOI":"10.1021\/acsinfecdis.9b00374","type":"journal-article","created":{"date-parts":[[2019,12,18]],"date-time":"2019-12-18T06:58:59Z","timestamp":1576652339000},"page":"820-831","source":"Crossref","is-referenced-by-count":19,"title":["Evaluation of\na Dual-Acting Antibacterial Agent, TNP-2092, on Gut Microbiota and\nPotential Application in the Treatment of Gastrointestinal and Liver\nDisorders"],"prefix":"10.1021","volume":"6","author":[{"given":"Ying","family":"Yuan","sequence":"first","affiliation":[{"name":"TenNor Therapeutics Limited , 218 Xinghu Street , Suzhou Industrial Park, ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Wang","sequence":"additional","affiliation":[{"name":"TenNor Therapeutics Limited , 218 Xinghu Street , Suzhou Industrial Park, ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyi","family":"Xu","sequence":"additional","affiliation":[{"name":"TenNor Therapeutics Limited , 218 Xinghu Street , Suzhou Industrial Park, ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6494-5092","authenticated-orcid":true,"given":"Yu","family":"Liu","sequence":"additional","affiliation":[{"name":"TenNor Therapeutics Limited , 218 Xinghu Street , Suzhou Industrial Park, ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cancan","family":"Li","sequence":"additional","affiliation":[{"name":"WuXi AppTec (Shanghai) Co., Ltd. , 288 Fute Zhong Road , Waigaoqiao, China (Shanghai) Pilot Free Trade Zone, ,","place":["Shanghai, China, 200131"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Yang","sequence":"additional","affiliation":[{"name":"WuXi AppTec (Shanghai) Co., Ltd. , 288 Fute Zhong Road , Waigaoqiao, China (Shanghai) Pilot Free Trade Zone, ,","place":["Shanghai, China, 200131"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqing","family":"Yang","sequence":"additional","affiliation":[{"name":"BGI Genomics , BGI Park, No.21 Hongan 3rd Street , Yantian District, ,","place":["Shenzhen, China, 518083"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-329X","authenticated-orcid":true,"given":"Zhenkun","family":"Ma","sequence":"additional","affiliation":[{"name":"TenNor Therapeutics Limited , 218 Xinghu Street , Suzhou Industrial Park, ,","place":["Suzhou, China, 215123"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2019,12,18]]},"reference":[{"issue":"9","key":"2026081806123022100_cit1","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1136\/gutjnl-2018-316723","article-title":"Human gut\nmicrobiome: hopes, threats and promises","volume":"67","author":"Cani","year":"2018","journal-title":"Gut"},{"key":"2026081806123022100_cit2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3920\/BM2017.0066","article-title":"Our gut microbiota: a long walk to\nhomeostasis","volume":"9","author":"Dicks","year":"2018","journal-title":"Benefic. Microbes"},{"key":"2026081806123022100_cit3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.mib.2014.11.010","article-title":"The rest of the\nstory: the microbiome and gastrointestinal infections","volume":"23","author":"Leslie","year":"2015","journal-title":"Curr. Opin. Microbiol."},{"key":"2026081806123022100_cit4","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/cmi.2018.7","article-title":"The microbiome\nand autoimmunity: aparadigm from the gut-liver axis","volume":"15","author":"Li","year":"2018","journal-title":"Cell. Mol. Immunol."},{"issue":"1","key":"2026081806123022100_cit5","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/nmo.12046","article-title":"Gut\nmicrobiota and gastrointestinal health: current concepts and future\ndirections","volume":"25","author":"Aziz","year":"2013","journal-title":"Neurogastroenterol. Motil."},{"issue":"5","key":"2026081806123022100_cit6","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00394-018-1844-5","article-title":"Non-alcoholic fatty liver disease and obesity: the\nrole of the gut bacteria","volume":"58","author":"Schwenger","year":"2019","journal-title":"Eur. J. Nutr."},{"issue":"1","key":"2026081806123022100_cit7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1097\/MPG.0000000000002205","article-title":"Fecal Microbiota\nTransplantation for Recurrent Clostridium difficile Infection and\nOther Conditions in Children: A Joint Position Paper From the North\nAmerican Society for Pediatric Gastroenterology, Hepatology, and Nutrition\nand the European Society for Pediatric Gastroenterology, Hepatology,\nand Nutrition","volume":"68","author":"Davidovics","year":"2019","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"issue":"7","key":"2026081806123022100_cit8","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1007\/s10096-019-03539-6","article-title":"Clostridium difficile infection:\nreview","volume":"38","author":"Czepiel","year":"2019","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"issue":"1","key":"2026081806123022100_cit9","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/ddr.21466","article-title":"Antibiotics as both friends and foes\nof the human gut microbiome: The microbial community approach","volume":"80","author":"Nogueira","year":"2019","journal-title":"Drug Dev. Res."},{"issue":"1","key":"2026081806123022100_cit10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijantimicag.2016.03.008","article-title":"Clostridium difficile infection following systemic antibiotic administration in randomised\ncontrolled trials: a systematic review and meta-analysis","volume":"48","author":"Vardakas","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"1","key":"2026081806123022100_cit11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41426-017-0019-4","article-title":"Advances in the\ndiagnosis and treatment of Clostridium difficile infections","volume":"7","author":"Peng","year":"2018","journal-title":"Emerging Microbes Infect."},{"issue":"7","key":"2026081806123022100_cit12","first-page":"455","article-title":"Antibiotics for the treatment of irritable bowel syndrome","volume":"7","author":"Basseri","year":"2011","journal-title":"Gastroenterol. Hepat."},{"key":"2026081806123022100_cit13","unstructured":"Xiong, Y. Q., Weiss, W. J., Doyle, T. B., Abdelsayed, G. A., and Bayer, A. S. (2007) Comparative Efficacy of CBR-2092 and Conventional Rifampin+Quinolone\nCombinations in Experimental Infective Endocarditis Caused by a Quinolone-Resistant\nMRSA. Presented at the 47th ICAAC Meeting, Chicago,\nIL. Poster no. F1-2108."},{"key":"2026081806123022100_cit14","article-title":"In vitro Activity of TNP-2092\nagainst Biofilms Formed by Prosthetic Joint Infection-Associated Staphylococci","author":"Fisher","year":"2019"},{"issue":"14","key":"2026081806123022100_cit15","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1021\/acs.jmedchem.6b00485","article-title":"Development\nof a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment\nof Persistent Bacterial Infections","volume":"59","author":"Ma","year":"2016","journal-title":"J. Med.\nChem."},{"issue":"43","key":"2026081806123022100_cit16","doi-asserted-by":"publisher","first-page":"12322","DOI":"10.3748\/wjg.v21.i43.12322","article-title":"Effect of\nrifaximin on gut microbiota composition inadvanced liver disease and\nits complications","volume":"21","author":"Ponziani","year":"2015","journal-title":"World J. Gastroenterol."},{"issue":"11","key":"2026081806123022100_cit17","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1111\/j.1365-2036.2010.04296.x","article-title":"Review article: rifaximin, a minimally absorbed oral\nantibacterial, for the treatment of travellers\u2019 diarrhoea","volume":"31","author":"Layer","year":"2010","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2026081806123022100_cit18","doi-asserted-by":"publisher","first-page":"309","DOI":"10.2147\/CEG.S89999","article-title":"Modulation\nof the gut microbiota composition by rifaximin in non-constipated\nirritable bowel syndrome patients: a molecular approach","volume":"8","author":"Soldi","year":"2015","journal-title":"Clin. Exp. Gastroenterol."},{"issue":"4","key":"2026081806123022100_cit19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1023\/A:1021989230535","article-title":"Pathophysiology of Hepatic Encephalopathy:\nA New Look at Ammonia","volume":"17","author":"Butterworth","year":"2002","journal-title":"Metab. Brain Dis."},{"issue":"3","key":"2026081806123022100_cit20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/S0002-9343(02)01477-8","article-title":"Correlation between ammonia levels\nand the severity of hepatic encephalopathy","volume":"114","author":"Ong","year":"2003","journal-title":"Am. J. Med."},{"issue":"3","key":"2026081806123022100_cit21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1128\/aem.37.3.379-382.1979","article-title":"Urease-producing species of intestinal\nanaerobes and their activities","volume":"37","author":"Suzuki","year":"1979","journal-title":"Appl. Environ.\nMicrobiol."},{"issue":"5","key":"2026081806123022100_cit22","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/j.1365-2958.1993.tb01220.x","article-title":"Bacterial ureases: structure, regulation\nof expression and role in pathogenesis","volume":"9","author":"Collins","year":"1993","journal-title":"Mol.\nMicrobiol."},{"issue":"8","key":"2026081806123022100_cit23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2174\/138920312804871094","article-title":"Bacterial Urease and its Role in Long-Lasting Human Diseases","volume":"13","author":"Konieczna","year":"2012","journal-title":"Curr. Protein Pept. Sci."},{"issue":"12","key":"2026081806123022100_cit24","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004472","article-title":"Microbial Urease in\nHealth and Disease","volume":"10","author":"Mora","year":"2014","journal-title":"PLoS Pathog."},{"issue":"10","key":"2026081806123022100_cit25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0109787","article-title":"THDP17 Decreases Ammonia Production\nthrough Glutaminase Inhibition. A New Drug for Hepatic Encephalopathy\nTherapy","volume":"9","author":"Di\u0301az-Herrero","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"2026081806123022100_cit26","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3109\/00365528509091662","article-title":"Increased Intestinal\nHydrolysis of Urea in Patients with Alcoholic Cirrhosis","volume":"20","author":"Hansen","year":"1985","journal-title":"Scand. J. Gastroenterol."},{"issue":"5","key":"2026081806123022100_cit27","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jhep.2010.05.017","article-title":"Role of small\nintestinal bacterial overgrowth and delayed gastrointestinal transit\ntime in cirrhotic patients with minimal hepatic encephalopathy","volume":"53","author":"Gupta","year":"2010","journal-title":"J. Hepatol."},{"key":"2026081806123022100_cit28","first-page":"292","article-title":"Effect of three antibacterial drugs\nin lowering blood & stool ammonia production in hepatic encephalopathy","volume":"96","author":"Alexander","year":"1992","journal-title":"Indian J. Med. Res."},{"key":"2026081806123022100_cit29","unstructured":"Wang, X., Wang, W., Teng, G., Chu, Y., Xie, Y., Wang, B., Lu, H., Xu, D., Yang, M., Wang, H., Lu, Y., and Ma, Z. (2016) Activity of dual-action molecule\nTNP-2092 against Helicobacter pylori clinical isolates collected from\nthree hospitals in China. Presented at the American\nSociety of Microbiology General Meeting, Poster no. 461."},{"key":"2026081806123022100_cit30","unstructured":"Weiss, W. J., Pulse, M., Nguyen, P., and Ma, Z. (2016) In Vivo Efficacy of Dual-Action Molecule TNP-2092\nin Mouse H. pylori Infection Model as Compared to\nTriple Therapies and Distribution within the Gastric Mucosal Layer. Presented at the American Society of Microbiology General Meeting,\nPoster no. 460."},{"issue":"3","key":"2026081806123022100_cit31","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1039\/C7FO01528C","article-title":"Gut:liver:brain axis: the microbial challenge in the\nhepatic encephalopathy","volume":"9","author":"Mancini","year":"2018","journal-title":"Food Funct."},{"issue":"02","key":"2026081806123022100_cit32","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1055\/s-0037-1602763","article-title":"The Human Gut Microbiome\nin Liver Diseases","volume":"37","author":"Davis","year":"2017","journal-title":"Semin. Liver Dis."},{"issue":"2","key":"2026081806123022100_cit33","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1002\/hep.24423","article-title":"Characterization of\nfecal microbial communities in patients with liver cirrhosis","volume":"54","author":"Chen","year":"2011","journal-title":"Hepatology"},{"issue":"2","key":"2026081806123022100_cit34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s11011-012-9303-0","article-title":"A longitudinal systems biology analysis\nof lactulose withdrawal in hepatic encephalopathy","volume":"27","author":"Bajaj","year":"2012","journal-title":"Metab. Brain Dis."},{"issue":"5","key":"2026081806123022100_cit35","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/j.jhep.2013.12.019","article-title":"Altered profile of human gut microbiome is associated\nwith cirrhosis and its complications","volume":"60","author":"Bajaj","year":"2014","journal-title":"J. Hepatol."},{"issue":"S1","key":"2026081806123022100_cit36","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/apt.13435","article-title":"Review\narticle: potential mechanisms of action of rifaximin in the management\nof hepatic encephalopathy and other complications of cirrhosis","volume":"43","author":"Bajaj","year":"2016","journal-title":"Aliment. Pharmacol. Ther."},{"key":"2026081806123022100_cit37","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/nature13568","article-title":"Alterations of the human gut microbiome\nin liver cirrhosis","volume":"513","author":"Qin","year":"2014","journal-title":"Nature"},{"issue":"1","key":"2026081806123022100_cit38","doi-asserted-by":"publisher","first-page":"G168","DOI":"10.1152\/ajpgi.00190.2011","article-title":"Linkage of gut microbiome with cognition in hepatic\nencephalopathy","volume":"302","author":"Bajaj","year":"2012","journal-title":"Am. J. Physiol. Gastrointest.\nLiver Physiol."},{"issue":"3","key":"2026081806123022100_cit39","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1179\/joc.2002.14.3.290","article-title":"Effects of Rifaximin Administration\non the Intestinal Microbiota in Patients with Ulcerative Colitis","volume":"14","author":"Brigidi","year":"2002","journal-title":"J. Chemother."},{"issue":"12","key":"2026081806123022100_cit40","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1093\/jac\/dkq345","article-title":"Rifaximin\nmodulates the colonic microbiota of patients with Crohn\u2019s disease:\nan in vitro approach using a continuous culture colonic model system","volume":"65","author":"Maccaferri","year":"2010","journal-title":"J. Antimicrob. Chemother."},{"issue":"4","key":"2026081806123022100_cit41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060042","article-title":"Modulation of the Metabiome by Rifaximin\nin Patients with Cirrhosis and Minimal Hepatic Encephalopathy","volume":"8","author":"Bajaj","year":"2013","journal-title":"PLoS One"},{"issue":"2","key":"2026081806123022100_cit42","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1053\/j.gastro.2013.10.026","article-title":"Rifaximin Alters Intestinal\nBacteria and Prevents Stress-Induced Gut Inflammation and Visceral\nHyperalgesia in Rats","volume":"146","author":"Xu","year":"2014","journal-title":"Gastroenterology"},{"issue":"3","key":"2026081806123022100_cit43","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1159\/000443361","article-title":"The Role of Antibiotics in Gut Microbiota\nModulation: The Eubiotic Effects of Rifaximin","volume":"34","author":"Ponziani","year":"2016","journal-title":"Dig. Dis."},{"issue":"6","key":"2026081806123022100_cit44","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1007\/s10620-013-2675-0","article-title":"The Effect of Rifaximin\non Gut Flora and Staphylococcus Resistance","volume":"58","author":"Kim","year":"2013","journal-title":"Dig. Dis. Sci."},{"key":"2026081806123022100_cit45","doi-asserted-by":"publisher","first-page":"S571","DOI":"10.1086\/432954","article-title":"Antibacterial Chemoprophylaxis in the Prevention of\nTraveler\u2019s Diarrhea: Evaluation of Poorly Absorbed Oral Rifaximin","volume":"41","author":"DuPont","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"2026081806123022100_cit46","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/nrgastro.2016.4","article-title":"Prevotella\nin the gut: choose carefully","volume":"13","author":"Ley","year":"2016","journal-title":"Nat. Rev. Gastroenterol.\nHepatol."},{"issue":"6","key":"2026081806123022100_cit47","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.cmet.2015.10.001","article-title":"Dietary Fiber-Induced Improvement in Glucose Metabolism\nIs Associated with Increased Abundance of Prevotella","volume":"22","author":"Kovatcheva-Datchary","year":"2015","journal-title":"Cell Metab."},{"key":"2026081806123022100_cit48","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.01202","article-title":"Expansion of intestinal Prevotella copri correlates\nwith enhanced susceptibility to arthritis","volume":"2","author":"Scher","year":"2013","journal-title":"eLife"},{"issue":"1","key":"2026081806123022100_cit49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1242\/dmm.017400","article-title":"How informative is the mouse for\nhuman gut microbiota research?","volume":"8","author":"Nguyen","year":"2015","journal-title":"Dis. Models\nMech."},{"issue":"3","key":"2026081806123022100_cit50","doi-asserted-by":"publisher","DOI":"10.1128\/MMBR.00007-19","article-title":"Gut Microbiota and Colonization Resistance\nagainst Bacterial Enteric Infection","volume":"83","author":"Ducarmon","year":"2019","journal-title":"Microbiol.\nMol. Biol. Rev."},{"key":"2026081806123022100_cit51","volume-title":"Methods for dilution antimicrobial susceptibility\ntests for bacteria that grow aerobically: approved standard","author":"Clinical\nLaboratory and Standards Institute","year":"2015","edition":"10"},{"key":"2026081806123022100_cit52","volume-title":"Methods for antimicrobial susceptibility testing\nof anaerobic bacteria: approved standard","author":"Clinical\nLaboratory and Standards Institute","year":"2007","edition":"7"}],"container-title":["ACS Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsinfecdis.9b00374","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/6\/5\/820\/12728971\/id9b00374.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article-pdf\/6\/5\/820\/12728971\/id9b00374.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T10:23:20Z","timestamp":1787048600000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/aidcbc\/article\/6\/5\/820\/1292919\/Evaluation-of-a-Dual-Acting-Antibacterial-Agent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,18]]},"references-count":52,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,12,18]]},"published-print":{"date-parts":[[2020,5,8]]}},"URL":"https:\/\/doi.org\/10.1021\/acsinfecdis.9b00374","relation":{},"ISSN":["2373-8227"],"issn-type":[{"value":"2373-8227","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,18]]}}}